Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

NCT03282318 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT03282318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03282318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2017
Completion date
March 21, 2019
Enrollment
119 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

bladder pain syndrome, interstitial cystitis